Onconetix Inc ONCO 深 沪
等待开盘 07-01 09:30:00 美东时间
1.13
+0.176
+18.41%
华盛通- 最 高1.18
- 今 开0.9383
- 成交量 100.98万股
- 最 低 0.9061
- 昨 收 0.9543
- 总市值 417.14万
- 52周最高 269.995
- 市盈率 静 --
- 换手率 27.35%
- 52周最低 0.88
- 委 比 59.51%
- 总股本 369.15万
- 历史最高 15453000.00
- 量 比 1.99
- 振 幅 28.70%
- 历史最低 0.9061
- 每 手 1
- 风险率 71.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Onconetix - Registers Up To 100 Million Shares For Resale By Keystone Capital Partners - SEC Filing
BRIEF-Onconetix - Registers Up To 100 Million Shares For Resale By Keystone Capital Partners - SEC Filing June 9 (Reuters) - Onconetix Inc ONCO.O : ONCONETIX - REGISTERS UP TO 100 MILLION SHARES FOR RESALE BY KEYSTONE CAPITAL PARTNERS - SEC FILING Source text: [] Further company coverage: ONCO.O ((
06-09 18:03
Onconetix shares are trading lower after the company announced a 1-for-10 reverse stock split.
Onconetix shares are trading lower after the company announced a 1-for-10 rever...
05-19 20:49
UPDATED: Onconetix Announces 1-For-10 Reverse Stock Split, Effective May 21, 2026
Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced
05-19 20:43
Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial results and issuing positive sales guidance. Other notable gainers and losers in pre-market trading include AMST, HAO, MTVA, ONCO, SDA, PIII, VRAX, PURR, BKKT, WOK, BTM, and UBXG.
05-19 16:47
Onconetix Q1 EPS $(6.71) Up From $(225.25) YoY, Sales $21.457K Down From $101.630K YoY
Onconetix (NASDAQ:ONCO) reported quarterly losses of $(6.71) per share. This is a 97.02 percent increase over losses of $(225.25) per share from the same period last year. The company reported $21.457 thousand in sales
05-13 21:48
Onconetix unit Proteomedix launches Proclarix U.S. validation study with Labcorp
Onconetix unit Proteomedix launches Proclarix U.S. validation study with Labcorp Onconetix reported Q1 2026 progress at wholly owned Swiss subsidiary Proteomedix, highlighting two peer-reviewed studies supporting Proclarix use to cut unnecessary prostate biopsies. Proteomedix initiated PRIME, a US m
05-13 21:26
Onconetix Q1 net loss narrows 50.7% to $4.21 million
Onconetix Q1 net loss narrows 50.7% to $4.21 million Onconetix posted net loss of $4.21 million, narrowing from year-earlier net loss applicable to common stockholders of $9.72 million. Revenue fell 78.9% to $21,457, swinging gross profit to gross loss of $1,655. Operating loss narrowed to $10.23 mi
05-13 20:52
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 56.4% to $0.16 du...
04-14 01:05
Onconetix Announces Realbotix Delivers Its First Vinci-Equipped Humanoid Robot To Ericsson
Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously
04-09 20:35
